Fostamatinib Skates Through OSKIRA-1 With Mixed Results

AstraZeneca/Rigel’s oral SYK inhibitor fostamatinib met a key primary endpoint in the first of three rheumatoid arthritis Phase III studies, but missed the other. Investors and analysts are underwhelmed with the efficacy results, although President and COO Raul Rodriguez advises holding on for the other Phase III trials before passing judgment.